Radioligand therapy with &lt;sup&gt;177&lt;/sup&gt;Lu-DOTA-PSMA in metastatic castration-resistant prostate cancer. Pharmacokinetics, safety, antitumour efficacy

В. Крылов, В.; S. Legkodimova, N.; Yu. Kochetova, T.; М. Петриев, В.; A. Sigov, M.; К. Тищенко, В.; И. Пронин, А.; Yu. Shurinov, A.; M. Petrosyan, K.; N. Spichenkova, O.; B. Karyakin, O.; A. Biryukov, V.; Stepanenko, Valeriy; П. Власова, О.; V. Shegaj, P.; А. Иванов, С.; Д. Каприн, А.

doi:10.22328/2079-5343-2022-13-4-75-85

Public

Radioligand therapy with <sup>177</sup>Lu-DOTA-PSMA in metastatic castration-resistant prostate cancer. Pharmacokinetics, safety, antitumour efficacy

Shared by NobleBlocks on Jan 17, 2023 • 12:00 AM UTC

Authors:

В. В. Крылов

N. S. Legkodimova

T. Yu. Kochetova

Abstract

INTRODUCTION: The results of studies of clinical potential of a new domestic radiopharmaceutical 177 Lu-DOTA-PSMA in patients with metastatic castration-resistant prostate cancer are presented in this article. OBJECTIVE: The pharmacokinetics, safety and tolerability of radiopharmaceutical were studi...

Subject

Medicine

DOTA

Prostate cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!